SuO-Glu-Val-Cit-PAB-MMAE CAS:1895916-24-1 is an advanced drug-linker conjugate designed for the development of antibody-drug conjugates (ADCs) in cancer therapy. This innovative compound features a potent tubulin inhibitor, monomethyl auristatin E (MMAE), coupled to a highly efficient and cleavable ADC linker, SuO-Glu-Val-Cit-PAB. The unique combination of the MMAE payload and the SuO-Glu-Val-Cit-PAB linker enables targeted delivery of the cytotoxic agent, leading to potent anti-tumor activity.
Applications:
SuO-Glu-Val-Cit-PAB-MMAE is a versatile research tool with potential applications in the design and optimization of ADCs for cancer therapy. Its superior conjugation efficiency and cleavable linker design make it an ideal candidate for the development of next-generation targeted drug delivery systems. The powerful MMAE payload, a tubulin inhibitor, disrupts microtubule dynamics, leading to cell cycle arrest and subsequent apoptosis in targeted cancer cells.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
